---
title: "Weekly Recap | Merck -4.26%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298793118.md"
description: "Merck (MRK) closed at $143.93, down 4.26% for the week, compared with a 0.8% pullback in the S&P 500 — an underperformance of about 3.46 percentage points. The decline took shape day by day: after opening higher on Tuesday at $148.41, the stock faded through Wednesday and Thursday and ended Friday just above its weekly low of $143.68. The 3.99% range and roughly in-line volume suggest a measured bout of profit-taking rather than a sharp sell-off."
datetime: "2026-09-12T06:21:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298793118.md)
  - [en](https://longbridge.com/en/news/298793118.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298793118.md)
generator: "portal-rs"
---

# Weekly Recap | Merck -4.26%, most brokers rate it buy

## The Week

Merck (MRK) closed at $143.93, down 4.26% for the week, compared with a 0.8% pullback in the S&P 500 — an underperformance of about 3.46 percentage points. The decline took shape day by day: after opening higher on Tuesday at $148.41, the stock faded through Wednesday and Thursday and ended Friday just above its weekly low of $143.68. The 3.99% range and roughly in-line volume suggest a measured bout of profit-taking rather than a sharp sell-off.

## Key Events

The week’s main company story was pipeline positioning ahead of the KEYTRUDA exclusivity window. On Sep 10, Merck said it was developing a roughly $70 billion pipeline to prepare for the loss of KEYTRUDA exclusivity. The same day, its M Ventures arm co-led a $62.5 million Series A for TwoStep Therapeutics. Earlier, Inhibrx reported mid-stage data showing INBRX-106 combined with pembrolizumab lifted the response rate to 48.3% in head and neck squamous cell carcinoma, adding another data point for KEYTRUDA combination use. By contrast, filings such as NewEdge Advisors adding 41,950 shares or Representative Salazar buying over $34k of stock carried limited informational weight.

## Analyst Ratings

Across 28 institutions covering MRK, 15 rate it buy, 5 overweight and 8 hold, with no underweight or sell ratings. The consensus rating is buy, with a consensus target price of $152.96, roughly 6.3% above the last close of $143.93. The target range is wide — from $105 to $186 — signalling clear disagreement over the post-patent-cliff earnings path. Within the pharma sector, MRK ranks 3rd out of 206 companies by analyst rating.

## The Week Ahead

On Sep 16, a batch of US retail and housing data lands: retail sales, retail sales ex-autos and the NAHB housing market index. Those prints will shape the read on consumer resilience. The next Merck-specific checkpoint is the Q3 FY2026 earnings release on Oct 29 pre-market, where estimates point to EPS of $1.90 and revenue of about $17.4 billion. Between now and then, any new KEYTRUDA combination trial data or licensing activity could shift the tone.

## In Short

MRK’s pullback this week ran alongside the long-standing patent-cliff anxiety, but the sell-side panel remains tilted positive: 20 of 28 analysts rate it buy or overweight, and the consensus target sits above spot. The offset is valuation — about 112x trailing P/E and 8.5x book — and a trading premium that has widened relative to Lilly. The next test is whether late-October earnings can show pipeline contribution, and how retail data affects overall risk appetite.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Merck says remigromig meets primary endpoint in pivotal BRUNELLO trial for diabetic macular edema](https://longbridge.com/en/news/300016853.md)
- [Merck's eye disease drug meets main goal in trial](https://longbridge.com/en/news/300019223.md)
- [Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data](https://longbridge.com/en/news/300461344.md)
- [What To Expect From Micron’s (MU) Q3 Earnings](https://longbridge.com/en/news/300373851.md)
- [Polymarket Odds: Will MU, FDS Beat Earnings Tomorrow?](https://longbridge.com/en/news/300470494.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**